9 completed, 6 terminated, 2 withdrawn, 1 active not recruiting. 20 Phase 1, 6 Phase 2.
Follow ADI PEG20: new trials by email Literature Review of ADI PEG20 trials Research Report on ADI PEG20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-11-09 |
| Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma ADI PEG20, Ifosfamide, Radiotherapy - Soft Tissue Sarcoma, Sts | Phase 1 | Terminated | Washington University School of Medicine | 6 | 2024-03-14 | 2026-09-03 |
| Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) ADI-PEG 20, Cabazitaxel, Carboplatin - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-02-29 | 2026-09-18 |
| A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma Atezolizumab, Bevacizumab, ADI-PEG 20 - Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-08-08 | 2024-08-26 | |
| ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers ADI-PEG 20, Gemcitabine, Docetaxel - Non Small Cell Lung Cancer, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Washington University School of Medicine | 31 | 2023-04-05 | 2026-07-27 |
| Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia ADI-PEG 20 - Acute Myeloid Leukemia, Adult | Phase 1 | Active not recruiting | Polaris Group | 38 | 2022-04-05 | 2026-10-15 |
| Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma ADI PEG20, Nivolumab, Ipilimumab - Uveal Melanoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 9 | 2019-04-16 | 2025-05-15 |
| Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin Atezolizumab, Pemetrexed, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 1 | Withdrawn | Queen Mary University of London | 2018-06-01 | 2020-02-25 | |
| Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers ADI PEG20, Pembrolizumab - Advanced Solid Cancers | Phase 1 | Terminated | Polaris Group | 33 | 2017-07-14 | 2022-04-27 |
| Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML ADI-PEG 20, Cytarabine - Acute Myeloid Leukemia | Phase 1 | Terminated | Polaris Group | 23 | 2017-01-20 | 2020-03-05 |
| Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer ADI-PEG 20 - Advanced Pancreatic Cancer | Phase 1 | Completed | Polaris Group | 21 | 2014-11-17 | 2020-10-01 |
| Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer ADI-PEG 20 - Hepatocellular Carcinoma | Phase 1 | Completed | Polaris Group | 8 | 2014-11-01 | 2016-03-04 |
| Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma ADI-PEG 20 plus modified FOLFOX6 - Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | Polaris Group | 140 | 2014-11-01 | 2022-04-25 |
| Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin ADI-PEG 20 - Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced | Phase 1 | Terminated | Polaris Group | 85 | 2014-04-23 | 2020-09-25 |
| Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer ADI-PEG 20 - HER2 Negative Metastatic Breast Cancer | Phase 1 | Completed | Polaris Group | 15 | 2014-04-01 | 2016-04-14 |
| Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma ADI-PEG 20 - Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors | Phase 1 | Completed | Polaris Group | 8 | 2012-09-01 | 2016-02-25 |
| Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient ADI-PEG 20 - Argininosuccinate Synthetase Deficient | Phase 1 | Completed | Polaris Group | 8 | 2011-12-01 | 2014-04-09 |
| Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer ADI-PEG 20 - Solid Tumors, Prostate Cancer | Phase 1 | Completed | Polaris Group | 43 | 2011-09-06 | 2018-09-13 |
| Study of ADI-PEG 20 in Patients With Advanced Melanoma ADI PEG 20 - Metastatic Melanoma, Skin Cancer | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 31 | 2007-07-01 | 2022-10-25 |
| ADI-PEG in Patients With Metastatic Melanoma ADI PEG - Melanoma, Neoplasm Metastasis | Phase 1 | Completed | FDA Office of Orphan Products Development | 15 | 2001-09-01 | 2015-03-25 |
Carcinoma, Hepatocellular (4) · Melanoma (3) · Uveal Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Glioma (2) · Leukemia, Myeloid, Acute (2) · Neoplasms (2) · Prostatic Neoplasms (2) · Carcinoma (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Ichthyosis, X-Linked (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Sarcoma (1)
Polaris Group (11) · M.D. Anderson Cancer Center (2) · Washington University School of Medicine (2) · FDA Office of Orphan Products Development (1) · Ludwig Institute for Cancer Research (1) · Memorial Sloan Kettering Cancer Center (1) · Queen Mary University of London (1) · Sabine Mueller, MD, PhD (1)
United States (17) · Taiwan (4) · United Kingdom (2) · China (1) · Italy (1) · South Korea (1)
Siqing Fu, MD (2) · Alexander Shoushtari, MD (1) · Ana Aparicio, MD (1) · Anna Pavlick, DO (1) · Christine Auberle, M.D. (1) · Cynthia Herzog, MD (1) · Gary Schwartz, MD (1) · Ghassan Abou-Alfa, MD (1) · James Harding, MD (1) · Jedd Wolchok, MD, PhD (1) · John S Bomalaski, MD (1) · Maeve Lowery, MD (1) · Mia Weiss, M.D. (1) · Peter Szlosarek (1) · Peter Szlosarek, MD, PhD (1)
PMID 22864522, PMID 30796035, PMID 33787078, PMID 34382365, PMID 35466524